Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 1
1973 1
1978 1
1987 2
1989 2
1990 3
1991 2
1992 3
1993 2
1994 3
1995 2
1997 5
1998 5
1999 2
2000 5
2001 2
2002 5
2003 6
2004 4
2005 5
2007 4
2008 8
2009 9
2010 9
2011 8
2012 15
2013 14
2014 19
2015 19
2016 25
2017 28
2018 43
2019 33
2020 61
2021 52
2022 49
2023 48
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20YJ, 5BAuthor
Page 1
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. Facon T, et al. Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19. Leukemia. 2020. PMID: 31427722 Free PMC article. Clinical Trial.
Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outcomes based on frailty using scores for age, Charlson Comorbidity Index (CCI), and Eastern Cooperative Oncology Group performance status (ECOG …
Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outco …
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Westin JR, et al. Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136. Clin Cancer Res. 2023. PMID: 36999993 Free PMC article. Clinical Trial.

In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum infla

…
In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global He …
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P. Scherpereel A, et al. Lung Cancer. 2022 May;167:8-16. doi: 10.1016/j.lungcan.2022.03.012. Epub 2022 Mar 21. Lung Cancer. 2022. PMID: 35367910 Free article. Clinical Trial.
Changes in disease-related symptom burden and health-related quality of life (HRQoL) were evaluated descriptively using the Lung Cancer Symptom Scale (LCSS)-Mesothelioma (Meso) average symptom burden index (ASBI), LCSS-Meso 3-item global index (3-IGI), 3-level EuroQol 5-dimension …
Changes in disease-related symptom burden and health-related quality of life (HRQoL) were evaluated descriptively using the Lung Cancer Symp …
[Pharmacotherapeutics for the new coronavirus pneumonia].
Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, Wang F, Sun B, Tong ZH. Du B, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):173-176. doi: 10.3760/cma.j.issn.1001-0939.2020.03.005. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32164081 Review. Chinese.
Vacuum-deposited Rb3CeI6 for deep-blue-light-emitting diodes.
Du H, Yang L, Pang J, Shen Z, Li J, Dong X, Luo Y, Luo J, Tang J. Du H, et al. Opt Lett. 2023 Jun 1;48(11):2777-2780. doi: 10.1364/OL.486168. Opt Lett. 2023. PMID: 37262208
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 427 nm and 468 nm. Due to the parity-allowed 5d-4f transition of Ce(III), the excited-state lifetime is as short as 22.3 ns (427 nm) an …
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 42 …
Detect-seq, a chemical labeling and biotin pull-down approach for the unbiased and genome-wide off-target evaluation of programmable cytosine base editors.
Lei Z, Meng H, Rao X, Zhao H, Yi C. Lei Z, et al. Nat Protoc. 2023 Jul;18(7):2221-2255. doi: 10.1038/s41596-023-00837-4. Epub 2023 Jun 5. Nat Protoc. 2023. PMID: 37277562 Review.
Programmable cytosine base editors show promising approaches for correcting pathogenic mutations; yet, their off-target effects have been of great concern. Detect-seq (dU-detection enabled by C-to-T transition during sequencing) is an unbiased, sensitive method for the off …
Programmable cytosine base editors show promising approaches for correcting pathogenic mutations; yet, their off-target effects have been of …
An EQ-5D-5L Value Set for Belgium.
Bouckaert N, Cleemput I, Devriese S, Gerkens S. Bouckaert N, et al. Pharmacoecon Open. 2022 Nov;6(6):823-836. doi: 10.1007/s41669-022-00353-3. Epub 2022 Aug 4. Pharmacoecon Open. 2022. PMID: 35927410 Free PMC article.
OBJECTIVE: This study aimed to establish a Belgian EQ-5D-5L value set based on the preferences of the adult Belgian general population. METHODS: The most recent EuroQol Valuation Technology (EQ-VT 2.1) protocol for EQ-5D-5L valuation studies was followed. Computer-a …
OBJECTIVE: This study aimed to establish a Belgian EQ-5D-5L value set based on the preferences of the adult Belgian general populatio …
Health utilities in burn injury survivors: A systematic review.
Synodinou D, Savoie-White FH, Sangone A, Chang SL, Beaudoin Cloutier C, Bergeron F, Guertin JR. Synodinou D, et al. Burns. 2022 Feb;48(1):13-22. doi: 10.1016/j.burns.2021.09.003. Epub 2021 Sep 17. Burns. 2022. PMID: 34844813 Review.
RESULTS: We identified 15 studies that reported burn injury survivors' utility scores. Most studies used the EQ-5D instruments to assess patients' utility scores. Results varied substantially between studies, ranging from a low of 0.06 to a high of 0.972. ...
RESULTS: We identified 15 studies that reported burn injury survivors' utility scores. Most studies used the EQ-5D instruments to ass …
Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone/Acylhydrazone Scaffolds.
Wang LP, Xu Z, Deng GY, Xu SL. Wang LP, et al. Curr Top Med Chem. 2020;20(21):1911-1915. doi: 10.2174/1568026620666200603105644. Curr Top Med Chem. 2020. PMID: 32493190
AIMS: A series of 8-methoxy ciprofloxacin- hydrazone/acylhydrazone hybrids were evaluated for their activity against a panel of cancer cell lines including HepG2 liver cancer cells, MCF-7, doxorubicin- resistant MCF-7 (MCF-7/DOX) breast cancer cells, DU-145 and multidrug-r …
AIMS: A series of 8-methoxy ciprofloxacin- hydrazone/acylhydrazone hybrids were evaluated for their activity against a panel of cancer cell …
460 results